10 results on '"Fujimura, Yoshihiro"'
Search Results
2. Candidate gene analysis using genomic quantitative PCR: identification of ADAMTS13 large deletions in two patients with Upshaw- Schulman syndrome.
- Author
-
Eura, Yuka, Kokame, Koichi, Takafuta, Toshiro, Tanaka, Ryojiro, Kobayashi, Hikaru, Ishida, Fumihiro, Hisanaga, Shuichi, Matsumoto, Masanori, Fujimura, Yoshihiro, and Miyata, Toshiyuki
- Subjects
GENES ,GENOMICS ,POLYMERASE chain reaction ,DELETION mutation ,BLOOD plasma ,EXONS (Genetics) - Abstract
Direct sequencing is a popular method to discover mutations in candidate genes responsible for hereditary diseases. A certain type of mutation, however, can be missed by the method. Here, we report a comprehensive genomic quantitative polymerase chain reaction ( qPCR) to complement the weakness of direct sequencing. Upshaw- Schulman syndrome ( USS) is a recessively inherited disease associated with severe deficiency of plasma ADAMTS13 activity. We previously analyzed ADAMTS13 in 47 USS patients using direct sequencing, and 44 of them had either homozygous or compound heterozygous mutations. Then, we sought to reveal more extensive defects of ADAMTS13 in the remaining three patients. We quantified copy numbers of each ADAMTS13 exon in the patients by using genomic qPCR. Each primer pair was designed to contain at least one of the two primers used in direct sequencing, to avoid missing any exonic deletions. The qPCR demonstrated heterozygous loss of exons 7 and 8 in one patient and exon 27 in the other, and further analysis revealed c.746_987+373del1782 and c.3751_3892+587del729, respectively. Genomic qPCR provides an effective method for identifying extensive defects of the target genes. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
3. ADAMTS13 unbound to larger von Willebrand factor multimers in cryosupernatant: implications for selection of plasma preparations for thrombotic thrombocytopenic purpura treatment.
- Author
-
Hori, Yuji, Hayakawa, Masaki, Isonishi, Ayami, Soejima, Kenji, Matsumoto, Masanori, and Fujimura, Yoshihiro
- Subjects
THROMBOTIC thrombocytopenic purpura ,VON Willebrand factor ,FROZEN blood ,BLOOD platelet aggregation ,BLOOD plasma ,PLASMA exchange (Therapeutics) ,MONOCLONAL antibodies - Abstract
Background Thrombotic thrombocytopenic purpura ( TTP) is characterized by deficient ADAMTS13 activity. Treatment involves plasma exchange ( PE). Both fresh-frozen plasma ( FFP) and cryosupernatant ( CSP) are used, but it remains to be determined which is more effective. Study Design and Methods To analyze the interaction between von Willebrand factor ( VWF) and ADAMTS13, we used large-pore isoelectric focusing ( IEF) analysis followed by detection with anti- ADAMTS13 monoclonal antibody. FFP, CSP, cryoprecipitate ( CP), and purified ADAMTS13 were analyzed for their effects on high shear stress-induced platelet aggregation ( H- SIPA). Results IEF analysis of normal plasma revealed three groups of ADAMTS13 bands with pI of 4.9 to 5.6, 5.8 to 6.7, and 7.0 or 7.5. Two band groups ( pI 4.9-5.6 and 5.8-6.7) were found in plasma of a patient with Type 3 von Willebrand disease, in which VWF is absent, whereas no bands were found in plasma of a patient with congenital ADAMTS13 deficiency. Mixing these plasmas generated the bands at pI 7.0 or 7.5, representing the VWF- ADAMTS13 complex; these bands were absent in CSP. FFP and purified ADAMTS13 down regulated H- SIPA in a dose-dependent manner. However, CP did not inhibit H- SIPA in the initial phase, and the degree of inhibition at the endpoint was almost indistinguishable from those of the other two plasma products. Conclusion Both plasma products ( FFP and CSP) are effective for PE in TTP patients. However, CSP may be more favorable, because it has lower levels of VWF and almost normal ADAMTS13 activity, but lower levels of ADAMTS13 in complex with larger VWF multimers. [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF
4. ADAMTS13 activity may predict the cumulative survival of patients with liver cirrhosis in comparison with the Child-Turcotte-Pugh score and the Model for End-Stage Liver Disease score.
- Author
-
Takaya, Hiroaki, Uemura, Masahito, Fujimura, Yoshihiro, Matsumoto, Masanori, Matsuyama, Tomomi, Kato, Seiji, Morioka, Chie, Ishizashi, Hiromichi, Hori, Yuji, Fujimoto, Masao, Tsujimoto, Tatsuhiro, Kawaratani, Hideto, Toyohara, Masahisa, Kurumatani, Norio, and Fukui, Hiroshi
- Subjects
ENZYME activation ,CIRRHOSIS of the liver ,BLOOD plasma ,GENETIC markers ,HEPATIC encephalopathy ,REGRESSION analysis ,LIVER diseases ,PATIENTS ,PROGNOSIS - Abstract
Aim: Decreased plasma ADAMTS13 activity (ADAMTS13:AC) results in accumulation of unusually large von Willebrand factor multimers and platelet thrombi formation. Our aim was to evaluate whether ADAMTS13:AC is a prognostic marker in patients with liver cirrhosis. Methods: Plasma ADAMTS13:AC and its related parameters were examined in 108 cirrhotic patients. Results: ADAMTS13:AC decreased as the severity of liver disease increased (means: controls 100%, Child A-cirrhotics 79%, Child B-cirrhotics 63%, and Child C-cirrhotics 31%). ADAMTS13:AC markedly decreased in the cirrhotics with hepatorenal syndrome, refractory ascites and hepatic encephalopathy. The cumulative survival time was the shortest (median: 4.5 months) in the cirrhotics with severe to moderate ADAMTS13:AC deficiency (<3-25%), followed by those with mild ADAMTS13:AC deficiency (25-50%), and was the longest in those with normal activity (>50%). In contrast, based on the Child-Turcotte-Pugh (CTP) score, Child C-cirrhotics had the worst survival, but the survival probabilities did not differ between Child A and B cirrhotics. Based on the Model for End-Stage Liver Disease (MELD) score, the survival was the worst for the cirrhotics in the fourth quartile, but it was not different among cirrhotics in the first three quartiles. Cox proportional-hazards regression analysis showed that ADAMTS13:AC and serum albumin were independent factors affecting the survival. Conclusions: ADAMTS13:AC concomitantly decreases as the functional liver capacity decreases. This activity may be a useful prognostic marker that is equal or superior to the CTP score and the MELD score to predict not only the short-term prognosis but also the long-term survival of the cirrhotic patients. [ABSTRACT FROM AUTHOR]
- Published
- 2012
- Full Text
- View/download PDF
5. Plasma ADAMTS13 activity parallels the APACHE II score, reflecting an early prognostic indicator for patients with severe acute pancreatitis.
- Author
-
Morioka, Chie, Uemura, Masahito, Matsuyama, Tomomi, Matsumoto, Masanori, Kato, Seiji, Ishikawa, Masatoshi, Ishizashi, Hiromichi, Fujimoto, Masao, Sawai, Masayoshi, Yoshida, Motoyuki, Mitoro, Akira, Yamao, Junichi, Tsujimoto, Tatsuhiro, Yoshiji, Hitoshi, Urizono, Yasuyuki, Hata, Michiaki, Nishino, Kenji, Okuchi, Kazuo, Fujimura, Yoshihiro, and Fukui, Hiroshi
- Subjects
PANCREATITIS ,MULTIPLE organ failure ,BLOOD plasma ,ENZYME-linked immunosorbent assay ,MORTALITY - Abstract
Objective. Severe acute pancreatitis (SAP) frequently progresses to pancreatitis-associated multiorgan failure (MOF) with high mortality. Decreased plasma ADAMTS13 activity (ADAMTS13:AC) results in the accumulation of unusually large von Willebrand factor multimers (UL-VWFM) and the formation of platelet thrombi, ultimately leading to MOF. The purpose of the study was to investigate the potential role of ADAMTS13:AC in the severity of SAP. Material and methods. Plasma ADAMTS13:AC and its related parameters were sequentially determined in 13 SAP patients. ADAMTS13:AC was determined by the chromogenic act-ELISA. Results. Within 1 or 2 days after admission, ADAMTS13:AC was lower in SAP patients (mean 28%) than in healthy controls (99%), and gradually recovered in the 11 survivors but further decreased in the 2 non-survivors. Patients with higher sepsis-related organ failure assessment (SOFA) scores showed lower ADAMTS13:AC than those without these scores. The inhibitor against ADAMTS13 was undetectable. On day 1, von Willebrand factor antigen (VWF:Ag) was higher (402%, p<0.001) in SAP patients than in controls (100%). VWF:Ag gradually decreased in the survivors, except in the 3 patients needing a necrosectomy, but remained high in the non-survivors. ADAMTS13:AC was inversely correlated with the APACHE II score (r=-0.750, p<0.005), and increased plasma concentrations of interleukin 6 (IL-6) and IL-8 at admission. UL-VWFM-positive patients had lower ADAMTS13:AC and decreased serum calcium concentrations, but higher VWF:Ag and IL-8 concentrations than UL-VWFM-negative patients. Conclusions. Plasma ADAMTS13:AC was closely related to the APACHE II score. This intimate relationship may serve as an early prognostic indicator for SAP patients. The imbalance between decreased ADAMTS13:AC and increased UL-VWFM could contribute to SAP pathogenesis through enhanced thrombogenesis. [ABSTRACT FROM AUTHOR]
- Published
- 2008
- Full Text
- View/download PDF
6. Novel monoclonal antibody-based enzyme immunoassay for determining plasma levels of ADAMTS13 activity.
- Author
-
Kato, Seiji, Matsumoto, Masanori, Matsuyama, Tomomi, Isonishi, Ayami, Hiura, Hisahide, and Fujimura, Yoshihiro
- Subjects
VON Willebrand factor ,BLOOD coagulation factors ,BLOOD proteins ,BLOOD platelets ,THROMBOCYTOPENIA ,BLOOD plasma - Abstract
BACKGROUND: ADAMTS13 specifically cleaves unusually large von Willebrand factor (VWF) multimers, which induce platelet thrombi formation under high shear stress. ADAMTS13 activity is deficient in patients with thrombotic thrombocytopenic purpura (TTP). The determination of plasma levels of ADAMTS13 activity is a prerequisite for a differential diagnosis of thrombotic microangiopathies. Here, a unique and highly sensitive enzyme immunoassay (EIA) of ADAMTS13 activity is described. STUDY DESIGN AND METHODS: ADAMTS13 hydrolyzes the peptide bond between Y1605 and M1606 of VWF. In this assay, a recombinant fusion protein (GST-VWF73-His) is used as a substrate. A panel of mouse monoclonal antibodies (MoAbs) that specifically recognizes Y1605, which is the C-terminal edge residue of the VWF-A2 domain and is generated by the enzymatic cleavage, has been produced. These antibodies were prepared with a synthetic decapeptide, termed N-10 (1596-DREQAPNLVY-1605), as the immunogen. Twenty-six clones specific to N10 were obtained, and one anti-N10 MoAb was used in this study. RESULTS: With horseradish peroxidase–conjugated anti-N10 MoAb, a standard enzyme assay was established. This assay was highly sensitive, and the detection limit was 0.5 percent of the normal. Further, an inhibitor of ADAMTS13 was measured to a level of 0.1 Bethesda units per mL. ADAMTS13 activity was measured in 20 patients with Upshaw-Schulman syndrome, a congenital TTP, and 61 acquired TTP patients. The activity measured by this assay and by the classic VWF multimer assay showed high correlation. CONCLUSION: A convenient and highly sensitive EIA for ADAMTS13 activity has been established. This assay can be introduced for routine laboratory work in transfusion medicine. [ABSTRACT FROM AUTHOR]
- Published
- 2006
- Full Text
- View/download PDF
7. Predicting response to plasma exchange in patients with thrombotic thrombocytopenic purpura with measurement of vWF-cleaving protease activity.
- Author
-
Mori, Yoshitaka, Wada, Hideo, Gabazza, Esteban C., Minami, Nobuyuki, Nobori, Tsutomu, Shiku, Hiroshi, Yagi, Hideo, Ishizashi, Hiromichi, Matsumoto, Masanori, and Fujimura, Yoshihiro
- Subjects
BLOOD plasma ,THROMBOTIC thrombocytopenic purpura ,PROTEOLYTIC enzymes - Abstract
Background: Severe deficiency of vWF-cleaving protease (vWF-CPase) activity was recently found in patients with thrombotic thrombocytopenic purpura (TTP). Although the survival of patients with TTP has been dramatically improved with plasma exchange (PE), there are still many patients who are refractory to PE and immunosuppressive therapy.Study Design and Methods: The activities of vWF-CPase and its inhibitor were measured in 27 patients with nonfamilial TTP and hemolytic-uremic syndrome (HUS) to examine the relationship between the clinical variables and vWF-CPase activity.Results: Eight of nine patients with HUS had more than 40 percent of vWF-CPase activity, whereas one had 28 percent of the normal level at the acute phase. Ten of 12 TTP patients with a good outcome had a severe deficiency of vWF-CPase activity and its inhibitor, whereas four of six patients with a poor outcome had a moderate deficiency of vWF-CPase activity along with a lack of the inhibitor. PE produced normalization of the vWF-CPase activity and neutralization of the inhibitor in TTP patients with a good outcome; however, some TTP patients with vWF-CPase inhibitor had relapsed and required an immunosuppressive therapy. The response to the combination therapy with PE and immunosuppressive treatment was poor in TTP patients without a severe deficiency of vWF-CPase activity.Conclusion: Assays of vWF-CPase activity and its inhibitor may be useful for predicting the response to therapy and the outcome of patients with TTP. In some patients, nonfamilial TTP with a poor prognosis may not be caused by a constitutional or acquired deficiency of vWF-CPase with its inhibitor. Although PE and immunosuppressive therapy are effective in patients with nonfamilial TTP and a vWF-CPase inhibitor, other therapeutic modalities may be needed for nonfamilial TTP with unknown etiology. [ABSTRACT FROM AUTHOR]- Published
- 2002
- Full Text
- View/download PDF
8. Highly elevated plasma level of von Willebrand factor accelerates the formation of platelet thrombus under high shear stress in plasma with deficient ADAMTS13 activity.
- Author
-
Tubaki, Kazuo, Yagi, Hideo, Yamaguchi, Naoko, Matsumoto, Masanori, Shida, Yasuaki, Sugimoto, Mitsuhiko, and Fujimura, Yoshihiro
- Subjects
- *
VON Willebrand factor , *THROMBOSIS , *BLOOD plasma , *GENETIC mutation , *PREGNANT women , *THROMBOTIC thrombocytopenic purpura , *GENETICS , *PHYSIOLOGY - Abstract
Upshaw-Schulman syndrome (USS) is a thrombo-hemorrhagic disease caused by congenital deficiency of ADAMTS13 due to ADAMTS13 gene mutations. USS is characterized by repeated episodes of thrombocytopenia and microangiopathic hemolytic anemia that respond dramatically to infusions of fresh frozen plasma. There are two phenotypic expressions of USS: one is the early-onset type and the other, the late-onset type, is asymptomatic during childhood with the first bout of thrombotic thrombocytopenic purpura (TTP) developing after adolescence or during adulthood. We found that gravida with the latter phenotype developed thrombocytopenia and hemolytic anemia during the second or third trimesters, often followed by thrombotic microangiopathies (TMAs). These phenomena suggest that elevated plasma von Willebrand Factor (VWF) might be crucial because plasma levels of VWF antigen usually increase by 200–500% during this period of gestation. Here, we performed platelet function assays using a mixture of anti-coagulated blood from normal volunteers, human VWF, anti-ADAMTS13 monoclonal antibody A10, and purified plasma-derived ADAMTS13 to investigate the effect of plasma VWF levels on platelet thrombus formation in the context of deficient ADAMTS13. In vitro studies showed that mural thrombus formation and platelet aggregation under high shear stress were markedly augmented by increasing the amounts of exogenously added VWF when ADAMTS13 activity was deficient, as may be the case in the in vivo circulation of gravida with USS. These results suggest that highly elevated plasma VWF might accelerate platelet thrombus formation not only in the circulation but also on the surface of vascular endothelial cells in the setting of ADAMTS13 deficiency in USS. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
9. Upshaw-Schulman syndrome diagnosed during pregnancy complicated by reversible cerebral vasoconstriction syndrome.
- Author
-
Tsuda, Mariko, Shiratsuchi, Motoaki, Nakashima, Yasuhiro, Ikeda, Motohiko, Muta, Hiroki, Narazaki, Taisuke, Masuda, Toru, Kimura, Daisaku, Takamatsu, Akiko, Matsumoto, Masanori, Fujimura, Yoshihiro, Kokame, Koichi, Matsushima, Takamitsu, and Ogawa, Yoshihiro
- Subjects
- *
VASOCONSTRICTION , *HEMODYNAMICS , *VASODILATION , *CEREBRAL arteries , *PLASMA exchange (Therapeutics) , *BLOOD plasma , *BLOOD transfusion - Abstract
Abstract Upshaw-Schulman syndrome (USS) is an inherited type of thrombotic thrombocytopenic purpura (TTP) that is extremely rare, but often diagnosed during pregnancy. Reversible cerebral vasoconstriction syndrome (RCVS) is the transient stenosis of several cerebral arteries that is frequently diagnosed post-partum. We describe a 28-year-old woman with USS complicated by RCVS after delivery that was treated by plasma exchange with a good outcome. She was referred to our hospital with thunderclap headache, anemia and thrombocytopenia that occurred immediately postpartum. She was diagnosed with TTP and multiple cerebral infarctions. Plasma exchange promptly improved her symptoms on hospital day 3. Moreover, multiple stenoses of cerebral arteries indicating RCVS were resolved. Since her sister also had an episode of thrombocytopenia during pregnancy, inherited TTP was suspected and genetic analyses confirmed USS. Pregnancy is a risk for not only TTP, but also RCVS. Endothelial damage might be an underlining cause and vasospasm after delivery is a trigger of RCVS. Plasma exchange was effective against both TTP and RCVS. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
10. Decreased ADAMTS13 activity in plasma from patients with thrombotic thrombocytopenic purpura
- Author
-
Kobayashi, Toshihiko, Wada, Hideo, Kamikura, Yuko, Matsumoto, Takeshi, Mori, Yoshitaka, Kaneko, Toshihiro, Nobori, Tsutomu, Matsumoto, Masanori, Fujimura, Yoshihiro, and Shiku, Hiroshi
- Subjects
- *
THROMBOTIC thrombocytopenic purpura , *BLOOD plasma , *PLASMA cell diseases , *THROMBOSPONDINS - Abstract
Abstract: The ADAMTS13 (a disintegrin and metalloprotease with thrombospondin type I domain 13) activity was measured by a fluorescence resonance energy transfer (FRET) assay in the plasma of healthy volunteers and thrombotic thrombocytopenic purpura (TTP) patients to examine its usefulness in the diagnosis of TTP. The plasma levels of the ADAMTS13 activity did not show a normal distribution. Its median value was 107% (range: 55–170%) in healthy volunteers, but was significantly lower in patients with TTP (acquired or familial) and in patients with hematopoietic stem cell transplantation. However, it was not significantly lower in patients with antiphospholipid syndrome (APS). The ADAMTS13 activity by a FRET assay was closely correlated with that by the ADAMTS13 multimer method (r =0.816; p <0.001). In 18 patients with less than 10% of ADAMTS13 activity by FRET assay, less than 10% of that by multimer assay was 16, thus suggesting a good correlation for a low level of ADAMTS13. These findings suggest that the ADAMTS13 FRET assay correlates well with the ADAMTS13 multimer method and it is therefore useful for making a diagnosis of TTP. [Copyright &y& Elsevier]
- Published
- 2007
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.